Salarius Pharma (SLRX): Rasio rega marang prakiraan pendapatan
Salarius Pharmaceuticals develops targeted therapies for rare tumors utilizing a flexible outsourcing model for production and research. The expected price-to-sales ratio reflects market expectations, where 20.40 determines this specific parameter level. However, the lack of profitability and a reliance on a narrow pipeline of experimental drugs create significant risks to business continuity.
Rincian analitis perusahaan Salarius Pharmaceuticals
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- rincian struktur utang lan likuiditas bisnis:
Total Utang marang Modal Salarius Pharmaceuticals|SLRX - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas salariuspharma.com|SLRX - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Salarius|SLRX - Gunggunge utang jangka dawa|Kewajiban jangka cendhak perusahaan Salarius Pharmaceuticals|Likuiditas cepet salariuspharma.com
- rincian asil keuangan lan kelipatan valuasi:
SLRX - Bathi sawise pajeg|Proyeksi bathi mangsa ngarep Salarius Pharmaceuticals|SLRX - Nilai perusahaan marang bathi resik|Pangali Forward P/E Salarius Pharma|SLRX - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Salarius Pharmaceuticals Inc|SLRX - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Salarius Pharmaceuticals|SLRX - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan salariuspharma.com|SLRX - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Salarius Pharmaceuticals
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:SLRX (Salarius Pharma)
Forward P/S measures the market value of a business relative to expected revenue, allowing for an assessment of an asset's margin of safety through the dynamics of future cash flows. By analyzing the forward P/S of the firm, an investor determines the degree of stock overvaluation, which is critical for Salarius Pharmaceuticals (SLRX), where liquidity risks and R&D costs for targeted inhibitors are already priced into the current exchange rate.
Analisis perusahaan pesaing
Multiplikator Forward P/S ONC (BeiGene Oncology)|Multiplikator Forward P/S Halozyme Corp HALO|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Group (AAPG) - Multiplikator forward rega marang pendapatan|CG Oncology Therapeutics (CGON) - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan UroGen Pharma URGN|Rasio rega marang prakiraan pendapatan Bicara Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Personalis Genomics PSNL|Multiplikator Forward P/S ERAS|Rasio rega marang pendapatan sing dikarepake DCTH|Y-mAbs Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Aura Biosciences Inc (AURA)|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc.)|SLS: Multiplikator Forward P/S|ACTU: Rasio rega marang pendapatan sing dikarepake|CTOR (Citius Oncology Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep tuhurabio.com HURA|Multiplikator Forward P/S TARA|FATE: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S WHWK (Aadi Bioscience)|TCRX (TScan) - Rega mangsa ngarep marang pendapatan|Champions Oncology, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake XBiotech Inc XBIT|CVM: Multiplikator Forward P/S|OSTX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Radiopharm Theranostics Limited|Multiplikator Forward P/S artivabio.com|Multiplikator forward rega marang pendapatan ANL (Adlai Nortye Limited)|Veru - Kapitalisasi marang prakiraan pendapatan|Tempest Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake xiliotx.com (XLO)|Renovaro - Multiplikator Forward P/S|Mural Oncology (MURA) - Multiplikator forward rega marang pendapatan|KAPA: Multiplikator Forward P/S|OKUR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan CytoMed Therapeutics Limited|CRIS: Rega forward marang dodolan|Multiplikator Forward P/S APLM|Multiplikator Forward P/S tharimmune.com (THAR)|Advanced Biomed Corp - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan GNPX|Calidi Biotherapeutics, Inc. - Multiplikator Forward P/S|Sunshine Biopharma (SBFM) - Multiplikator forward rega marang pendapatan|XBIO: Multiplikator Forward P/S|Purple Biotech Ltd. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan AON|Multiplikator Forward P/S BeiGene Ltd.|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|Multiplikator forward rega marang pendapatan Elevation Oncology, Inc. ELEV|Multiplikator Forward P/S ICAD (iCAD Inc.)|IKNA - Multiplikator forward rega marang pendapatan|NTBL: Multiplikator forward rega marang pendapatan|viracta.com (VIRX) - Multiplikator forward rega marang pendapatan|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Corp (NAYA) - Multiplikator Forward P/S|AAPGV (Ascentage) - Multiplikator Forward P/S
